Vivesto reports positive results from Cantrixil PK/toxicology study
The study shows Cantrixil was well tolerated intravenously in dogs, supporting development toward Phase I in AML.
See the latest news and media coverage for Vivesto. We track all announcements, press releases, and industry mentions in real time, all in one place.
Swedish oncology drug development company
vivesto.comLast updated
In short: Vivesto reported positive toxicology results for Cantrixil, completed a reverse share split, and appointed Björn Svanström as the new CFO.
The study shows Cantrixil was well tolerated intravenously in dogs, supporting development toward Phase I in AML.
He will take up the role on July 1, 2026, succeeding Robert Maiorana.
The total number of shares and votes decreased by over 1 billion to 11,071,369.
The reverse share split of 1:100 was approved at the AGM on 7 May 2026, with record date 21 May 2026.
Visit a quote page and your recently viewed tickers will be displayed here.
At close: 17 April at 16:00:00 GMT-4...
At the Annual General Meeting in Vivesto AB ("Vivesto" or the "company") held on 7 May 2026, the following resolutions were passed. All resolutions were...
The Board of Directors of the research company Vivesto proposes that the Annual General Meeting on May 7 resolve on a reverse stock split, whereby...
Track Vivesto and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Vivesto and other trending companies.